Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.49 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18310129 | 0.90 | NPC1 (0.62) | NPC1PKMRAB9AACHEBACE1 | |
| SCHEMBL16991973 | 0.83 | NPC1 (0.55) | NPC1PKMRAB9AACHEBACE1 | |
| SCHEMBL14782977 | 0.82 | HPGD (0.55) | NPC1PKMRAB9AACHEBACE1 | |
| SCHEMBL25720038 | 0.81 | MEN1 (0.55) | NPC1PKMRAB9AACHEBACE1 | |
| SCHEMBL6336112 | 0.78 | ERCC1 (0.69) | NPC1PKMRAB9AACHEBACE1 | |
| SCHEMBL14782827 | 0.77 | ERCC1 (0.53) | NPC1PKMRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL3264766 | 0.77 | BDKRB1 (0.53) | NPC1PKMRAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL4242416 | 0.77 | POLB (0.62) | NPC1RAB9AACHEBACE1ALDH1A1 | |
| SCHEMBL5503225 | 0.77 | PPARG (0.51) | NPC1RAB9AALDH1A1SMN1; SMN2HSD17B10 | |
| SCHEMBL24822576 | 0.76 | ALDH1A1 (0.50) | ALDH1A1POLBHPGDLMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-11786524-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2023-10-17 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | SENTINEL ONCOLOGY LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| EP-3811944-A1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | Sentinel Oncology Limited (GB) | 2021-04-28 | — | — | EP | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| US-10973817-B2 | Pharmaceutical compounds | SENTINEL ONCOLOGY LIMITED (GB) | 2021-04-13 | — | — | US | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| EP-3104860-B1 | PHARMACEUTICAL COMPOUNDS AS CHK1 INHIBITORS | SENTINEL ONCOLOGY LTD (GB) | 2020-12-30 | — | — | EP | disclosed |
| CN-110143950-A | Medical compounds | 西雅图遗传学公司 | 2019-08-20 | — | — | CN | disclosed |
| CN-106170288-B | Pharmaceutical compounds | 西雅图遗传学公司 | 2019-07-19 | — | — | CN | disclosed |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CASCADIAN THERAPEUTICS, INC. (US) | 2018-09-27 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010547-B2 | Pharmaceutical compounds | CASCADIAN THERAPEUTICS, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| EP-3104860-A1 | PHARMACEUTICAL COMPOUNDS | Cascadian Therapeutics, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | SEATTLE GENETICS, INC. | 2016-12-15 | — | — | US | disclosed |
| CN-106170288-A | Pharmaceutical compounds | 卡斯卡迪安疗法公司 | 2016-11-30 | — | — | CN | disclosed |
| WO-2015120390-A1 | PHARMACEUTICAL COMPOUNDS | ONCOTHYREON INC. (US) | 2015-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10010547-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
| US-20180271860-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
| US-11786524-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
| US-20160361310-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
| US-20210275525-A1 | PHARMACEUTICAL COMPOUNDS | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
| US-10973817-B2 | Pharmaceutical compounds | CHKA, CHKB, TNK2 | NPC1 306/4885PKM 397/4885RAB9A 1682/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.